Sunphenon

Phase 2Small molecule

HH. Lee Moffitt Cancer Center and Research Institute

Sunphenon is one of 2 small molecule programs targeting Active Surveillance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Active SurveillanceActive, not recruiting

Active SurveillancePhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Active Surveillance

#DrugCompanyPhaseTrials

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

Sunphenon

HH. Lee Moffitt Cancer Center and Research Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Active Surveillance

NCT04300855

Clinical

Trials by Indication[1]

Active Surveillance1 trial

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04300855·115 enrolled

Prostate Cancer1 trial

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

Terminated·—·Phase 2·NCT01928485·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sunphenon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sunphenon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sunphenon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — H. Lee Moffitt Cancer Center and Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HH. Lee Moffitt Cancer Center and Research Institute

Sunphenon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Active Surveillance1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News